| Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease RS Doody, RG Thomas, M Farlow, T Iwatsubo, B Vellas, S Joffe, ... New England Journal of Medicine 370 (4), 311-321, 2014 | 1868 | 2014 |
| Axonopathy and transport deficits early in the pathogenesis of Alzheimer's disease GB Stokin, C Lillo, TL Falzone, RG Brusch, E Rockenstein, SL Mount, ... Science 307 (5713), 1282-1288, 2005 | 1460 | 2005 |
| A phase 3 trial of semagacestat for treatment of Alzheimer's disease RS Doody, R Raman, M Farlow, T Iwatsubo, B Vellas, S Joffe, K Kieburtz, ... New England Journal of Medicine 369 (4), 341-350, 2013 | 1368 | 2013 |
| Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial JF Quinn, R Raman, RG Thomas, K Yurko-Mauro, EB Nelson, C Van Dyck, ... Jama 304 (17), 1903-1911, 2010 | 927 | 2010 |
| A randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease RS Turner, RG Thomas, S Craft, CH Van Dyck, J Mintzer, BA Reynolds, ... Neurology 85 (16), 1383-1391, 2015 | 694 | 2015 |
| The preclinical Alzheimer cognitive composite: measuring amyloid-related decline MC Donohue, RA Sperling, DP Salmon, DM Rentz, R Raman, ... JAMA neurology 71 (8), 961-970, 2014 | 693 | 2014 |
| Clinical Core of the Alzheimer's Disease Neuroimaging Initiative: progress and plans PS Aisen, RC Petersen, MC Donohue, A Gamst, R Raman, RG Thomas, ... Alzheimer's & Dementia 6 (3), 239-246, 2010 | 548 | 2010 |
| Giant cell arteritis: validity and reliability of various diagnostic criteria SS Hayreh, PA Podhajsky, R Raman, B Zimmerman American journal of ophthalmology 123 (3), 285-296, 1997 | 500 | 1997 |
| Efficacy of site-independent telemedicine in the STRokE DOC trial: a randomised, blinded, prospective study BC Meyer, R Raman, T Hemmen, R Obler, JA Zivin, R Rao, RG Thomas, ... The Lancet Neurology 7 (9), 787-795, 2008 | 469 | 2008 |
| Intravenous thrombolysis plus hypothermia for acute treatment of ischemic stroke (ICTuS-L) final results TM Hemmen, R Raman, KZ Guluma, BC Meyer, JA Gomes, S Cruz-Flores, ... Stroke 41 (10), 2265-2270, 2010 | 444 | 2010 |
| Phase 2 safety trial targeting amyloid β production with a γ-secretase inhibitor in Alzheimer disease AS Fleisher, R Raman, ER Siemers, L Becerra, CM Clark, RA Dean, ... Archives of neurology 65 (8), 1031-1038, 2008 | 443 | 2008 |
| World‐Wide FINGERS Network: a global approach to risk reduction and prevention of dementia M Kivipelto, F Mangialasche, HM Snyder, R Allegri, S Andrieu, H Arai, ... Alzheimer's & dementia 16 (7), 1078-1094, 2020 | 419 | 2020 |
| Safety, efficacy, and feasibility of intranasal insulin for the treatment of mild cognitive impairment and Alzheimer disease dementia: a randomized clinical trial S Craft, R Raman, TW Chow, MS Rafii, CK Sun, RA Rissman, ... JAMA neurology 77 (9), 1099-1109, 2020 | 313 | 2020 |
| Effect of head impacts on diffusivity measures in a cohort of collegiate contact sport athletes TW McAllister, JC Ford, LA Flashman, A Maerlender, RM Greenwald, ... Neurology 82 (1), 63-69, 2014 | 296 | 2014 |
| Quetiapine for agitation or psychosis in patients with dementia and parkinsonism R Kurlan, J Cummings, R Raman, L Thal Neurology 68 (17), 1356-1363, 2007 | 268 | 2007 |
| Association of factors with elevated amyloid burden in clinically normal older individuals RA Sperling, MC Donohue, R Raman, CK Sun, R Yaari, K Holdridge, ... JAMA neurology 77 (6), 735-745, 2020 | 263 | 2020 |
| Alzheimer’s Disease Cooperative Study Steering Committee; Solanezumab study group. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer’s disease RS Doody, RG Thomas, M Farlow, T Iwatsubo, B Vellas, S Joffe, ... N Engl J Med 370 (4), 311-321, 2014 | 260 | 2014 |
| Hallucinations, sleep fragmentation, and altered dream phenomena in Parkinson's disease EJ Pappert, CG Goetz, FG Niederman, R Raman, S Leurgans Movement disorders: official journal of the Movement Disorder Society 14 (1 …, 1999 | 248 | 1999 |
| Poor visual discrimination and visual hallucinations in Parkinson's disease NJ Diederich, CG Goetz, R Raman, EJ Pappert, S Leurgans, V Piery Clinical neuropharmacology 21 (5), 289-295, 1998 | 240 | 1998 |
| Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease PN Tariot, LS Schneider, J Cummings, RG Thomas, R Raman, ... Archives of General Psychiatry 68 (8), 853-861, 2011 | 237 | 2011 |
